Insmed Phase 3 lung med study meets primary endpoint

Insmed announced that detailed data from its ongoing Phase 3 CONVERT study of ALIS in adult patients with treatment refractory NTM lung disease caused by MAC were presented at the American Thoracic Society, or ATS 2018 International Conference. Results from 336 randomized patients in the Phase 3 CONVERT study cumulatively demonstrated that ALIS, combined with GBT, improved culture conversion rates. The global CONVERT study met its primary endpoint of culture conversion by month six with statistical significance. In the study, the addition of ALIS to GBT eliminated evidence of NTM lung disease caused by MAC in sputum by month six in 29% of patients, compared to 9% of patients on GBT alone. Additionally, results from an exploratory analysis using the 6MWT, a quality of life measure, demonstrated that converters from both groups saw a mean increase in distance walked at month six of 16.8 meters as compared to baseline

https://bit.ly/2s65Ofk